Age effects on survival from early breast cancer in clinical settings in Australia

Roder, David; Silva, Primali de; Zorbas, Helen; Kollias, James; Malycha, Peter; Pyke, Chris; Campbell, Ian

doi:10.1111/j.1445-2197.2012.06114.x

Cited by 19 publications

(10 citation statements)

References 16 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the larger Slovenian cohort, these patients also had worse BCSS, compared to patients aged 40–70 years, but no worse than patients under 40. Similar trends have been reported in other countries (20).…”

Section: Discussionsupporting

confidence: 90%

Survival of node-negative breast cancer patients treated at the university medical centre Maribor in the period 2000–2009

Dovnik

Arko

Sikošek

et al. 2017

Slovenian Journal of Public Health

View full text Add to dashboard Cite

IntroductionBreast cancer is increasingly diagnosed in the early stages without regional nodal involvement. The aim of the present study was to determine the 5-year overall (OS) and breast cancer specific survival (BCSS) for patients with node-negative breast cancer treated at the University Medical Centre Maribor, and compare it with survival at the national level.MethodsMedical records were searched for information on patients with lymph node-negative invasive breast cancer who received primary treatment at the University Medical Centre Maribor in the period 2000–2009. Information on all Slovenian node-negative breast cancer patients diagnosed in the same period was obtained from the Cancer Registry of Republic of Slovenia. Time trends in survival were assessed by comparing the periods 2000–2004 and 2005–2009.ResultsThe 5-year OS and BCSS of patients treated in Maribor in the period 2000–2009 were 92.3% (95% CI, 90.5%– 94.1%) and 96.4% (95% CI, 95.2%–97.6%), respectively, and did not differ from the corresponding OS and BCSS for Slovenian patients. Although the improvement in OS for patients from Maribor diagnosed in the period 2005–2009 compared to 2000–2004 did not reach statistical significance (HR 0.73; 95% CI, 0.51–1.05; p=0.086), BCSS significantly improved over the same time periods (HR 0.53; 95% CI, 0.30–0.94; p=0.028).ConclusionsSurvival of node-negative breast cancer patients treated at the University Medical Centre Maribor is comparable to survival of corresponding patients at the national level. The rising number of long-term breast cancer survivors places additional importance on survivorship care.

show abstract

Section: Discussionsupporting

confidence: 90%

Survival of node-negative breast cancer patients treated at the university medical centre Maribor in the period 2000–2009

Dovnik

Arko

Sikošek

et al. 2017

Slovenian Journal of Public Health

View full text Add to dashboard Cite

show abstract

“…Balabram et al[20] performed a retrospective cohort study of 767 breast cancer patients in Brazil, the results of which indicated that women aged ≥70 and ≤35 exhibited shorter cancer-specific survival than patients aged between 36 and 69 years. Roder et al[21] analysed 493 breast cancer patients diagnosed from 1998–2005 in Australia and found that women under 40 years and over 70 years exhibited poorer overall survival than women between 40 and 69 years. Similarly, Brandt et al[12] studied 4,453 women who were diagnosed with breast cancer between 1961 and 1991 at a single institution in Sweden and were followed up for 10 years regarding breast cancer-specific mortality.…”

Section: Discussionmentioning

confidence: 99%

Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database

et al. 2016

View full text Add to dashboard Cite

BackgroundAge is an important risk factor for breast cancer, but data regarding whether patient age at diagnosis is related to breast cancer survival are conflicting. This population-based study evaluated the effect of age on breast cancer prognosis and identified outcome-related factors.Patients and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database and enrolled female primary non-metastatic cases. Patients were subdivided into seven groups, and analyses of the associations between age and overall survival (OS) and breast cancer-specific survival (BCSS) were carried out using the Kaplan-Meier method and Cox regression model, respectively. We also assessed differences in survival among three specific age groups, using the ages of 30 and 50 years as cut-offs. Stratified analyses regarding race, histology, grade, stage and hormone receptor status were also carried out.ResultsA total of 133,057 female patients diagnosed with breast cancer from 2004 to 2008 were included in the current study (6.4% <40 years), Women aged 40 to 49 years and 60 to 69 years exhibited significantly better OS and BCSS, respectively (log-rank, p<0.001), than their counterparts in other groups. Middle-aged women exhibited distinctly better OS (log-rank, p<0.001) and BCSS (log-rank, p<0.001) than their counterparts in the other two age groups. Following adjustments for potential confounding factors, middle-age at breast cancer diagnosis was shown to be an independent predictor of favourable outcomes in terms of OS, but not BCSS (for OS, HR, 0.92; 95%CI, 0.87–0.98; p = 0.007; for BCSS, HR, 0.94; 95%CI, 0.80–1.01; p = 0.075, using the young group as reference). Stratified analysis showed that middle-age was significantly associated with increased survival, except among patients with stage III disease, and that elderly women faced worse prognoses than younger patients.ConclusionOur results indicate that younger breast cancer patients exhibit more aggressive disease than older patients. Middle-aged patients exhibit better OS and BCSS than young and elderly patients but exhibit BCSS rates similar to those of young patients after adjustments for confounders. Stratified analysis demonstrated that middle-aged patients exhibited better survival than young patients, with the exception of patients with stage III disease. An age of 60 years or more was a significant independent predictor of a poor prognosis.

show abstract

“…The correlation of various factors with rate of survival after BC diagnosis has been evaluated and shown in different studies. For instance, Roder et al, (2012) showed that tumor size, stage of tumor, involvement of lymph nodes, estrogen receptor (ER) status, vascular status and being diffused correlate with survival rate after being diagnosed with BC. Dong et al, (2014) added menopausal status, and metastasis to armpit lymph nodes and the adjacent region to the factors correlating with survival after BC development (Dong et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

5-Year Survival Rates and Prognostic Factors in Patients with Synchronus and Metachronus Breast Cancer from 2010 to 2015

Sarveazad

Babahajian

Shamseddin

et al. 2018

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Introduction: Currently breast (BC) cancer is a serious medical problem in all countries of the world. Survival depends on many factors. The present study focused on 5-year survival and its related factors in patients with BC in Iran. Material and methods. The present analytical retrospective study was performed (from March 2010 until March 2015) on patients with BC followed for at least 6 months. The main variables assessed were tumor size, grade of lymph node involvement, metastasis, stage, history, human epidermal growth factor receptor expression, and tumor origin. Analysis of survival was accomplished using the Kaplan- Meier method. Results: Some 351 (80.2%) of the total of 438 individuals had unilateral and 87(19.8%) had bilateral cancer, 28 (35.6%) of the latter being synchronous and 56(64.4%) metachronous. Mean duration of follow-up was 47.44±28.19 months, during which 61 (17.3%) patients with unilateral and 18 with bilateral cancer eventually died. The 5-year survival rate in patients with unilateral BC was significantly higher than those with bilateral BC (Log-rank Test chi2= 3.11, p=0.032). In addition, with metachronous cases, the survival rate was 64.2% in comparison with 51.6% for synchronous BCs. Survival rate was significantly (p value =0.038) higher with metachronous than with synchronous cancers (Log-rank Test chi2=3.54, p=0.038). The highest survival rate was reported for BCs originating from lobule tissue and the lowest rate examples of interstitial tissue origin (Log-rank Test chi2=11.54, p=0.0001). Patients with earl stage lesions (M1) survived longer than with other stages (Log-rank Test chi2= 9.55, p=0.001). Conclusion: In this study, most women with BC had a positive family history and were married. The 5-year survival rate was lower with advanced stages of cancer. According to our findings, survival rates might improve if patients undergo screening and diagnosis is made at an early stage of the disease.

show abstract

Age effects on survival from early breast cancer in clinical settings in Australia

Cited by 19 publications

References 16 publications

Survival of node-negative breast cancer patients treated at the university medical centre Maribor in the period 2000–2009

Survival of node-negative breast cancer patients treated at the university medical centre Maribor in the period 2000–2009

Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database

5-Year Survival Rates and Prognostic Factors in Patients with Synchronus and Metachronus Breast Cancer from 2010 to 2015

Contact Info

Product

Resources

About